Jacobio Pharmaceuticals Co., Ltd.
This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 Monotherapy and in Combination with Other Agents in adult participants with advanced solid tumors
This is a multi-part, open-label, multi-center Phase 1/2a study evaluating JAB-23E73 as monotherapy (Part A) and in combination with other agents (Part B1: with cetuximab) in adult participants with advanced solid tumors. Part A will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anticancer activity of JAB-23E73 as a single agent in adult patients with advanced solid tumors with KRAS alteration. Part A consists of three phases: Phase 1a dose-escalation, Phase 1b dose expansion (dose optimization), and Phase 2a indication expansion. Part B1 will evaluat…
Inclusion Criteria: * Written informed consent. * Participant must be ≥18 years of age at the time of signing the Informed Consent Form (ICF). * Histologically or cytologically confirmed locally advanced or metastatic solid tumors that are not suitable for curative interventions and who have received relevant prior systemic therapy.(Part A) * Histologically/cytologically confirmed unresectable locally advanced or metastatic CRC who progressed on or were intolerant to ≥1 standard systemic regimen with fluorouracil derivatives, oxaliplatin, irinotecan, FDA-approved immunotherapy or targeted the…
Oral administration
Intravenous infusion
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.